ReviewCurrent opinion in lipidology2016
Effects of melatonin on cardiovascular diseases: progress in the past year.
Review in Current opinion in lipidology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Melatonin and the cardiovascular system in animals: systematic review and meta-analysis.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- Melatonin Therapy Improves Cardiac Autonomic Modulation in Pinealectomized Patients.Frontiers in endocrinology · 2020Trial
- Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms.Cancer cell international · 2026Review
- Photoelectrochemical sensor based on Au/FeFrontiers in chemistry · 2026Article
- The Chronological Trigger: The Orchestra Between Homeobox Genes and the Circadian Clock During Development.Biology of the cell · 2025Review
- Effect of melatonin on passive, ex-vivo biomechanical behavior of lamb esophagus.Scientific reports · 2025Article
- SIRT1: The first key to unlocking the mystery of cardiovascular diseases.Frontiers in pharmacology · 2025Review
- Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats.Frontiers in pharmacology · 2024Article
- Melatonin stabilizes atherosclerotic plaques: an association that should be clinically exploited.Frontiers in medicine · 2024Review
- Design, synthesis, molecular docking and DFT studies on novel melatonin and isatin based azole derivatives.RSC advances · 2023Article
- Melatonin alleviates lung injury in H1N1-infected mice by mast cell inactivation and cytokine storm suppression.PLoS pathogens · 2023Article
- Melatonin Treatment in Kidney Diseases.Cells · 2023Review
- Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases.International journal of molecular sciences · 2023Review
- ROS-dependent catalytic mechanism of melatonin metabolism and its application in the measurement of reactive oxygen.Frontiers in chemistry · 2023Article
- Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease.Frontiers in immunology · 2023Article
- Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives.Frontiers in pharmacology · 2023Review
- Shared Lifestyle-Related Risk Factors of Cardiovascular Disease and Cancer: Evidence for Joint Prevention.TheScientificWorldJournal · 2023Review
- Remote ischemic preconditioning-induced late cardioprotection: possible role of melatonin-mitoKATP-H2S signaling pathway.Acta cirurgica brasileira · 2023Article
- Can melatonin reduce the severity of post-COVID-19 syndrome?EXCLI journal · 2023Review
- Hypotensive effects of melatonin in rats: Focus on the model, measurement, application, and main mechanisms.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMelatonin is a neuroendocrine hormone synthesized primarily by the pineal gland. Numerous studies have suggested that melatonin plays an important role in various cardiovascular diseases. In this article, recent progress regarding melatonin's effects on cardiovascular diseases is reviewed. RECENT
findingsIn the past year, studies have focused on the mechanism of protection of melatonin on cardiovascular diseases, including myocardial ischemia-reperfusion injury, myocardial hypoxia-reoxygenation injury, pulmonary hypertension, hypertension, atherosclerosis, valvular heart diseases, and other cardiovascular diseases. SUMMARY: Studies have demonstrated that melatonin has significant effects on ischemia-reperfusion injury, myocardial chronic intermittent hypoxia injury, pulmonary hypertension, hypertension, valvular heart diseases, vascular diseases, and lipid metabolism. As an inexpensive and well tolerated drug, melatonin may be a new therapeutic option for cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.